Company intelligence / Profile preview
Sun Ten
- Ownership
- Private
- Development stage
- Other
Overview
Sun Ten is a global leader in the manufacture of high-quality, standardized herbal remedies that blend traditional Chinese medicine with modern pharmaceutical science. Its innovative compound RespireAid gained international recognition for reducing the risk of severe COVID outcomes and is available as a dietary supplement or medicine in multiple countries. The company has also collaborated on clinical research with major academic institutions such as Yale University[1]. Most products are commercialized; some have been tested in combination therapy trials for cancer supportive care[1].
- Therapeutic areas
- GastroenterologyPulmonologyWomen's HealthImmunology
- Modalities
- Herbal extractBotanical drugDietary supplement
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Sun Ten.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sun Ten.